The aim of the present study was to investigate whether K V 3.4 channel subunits are involved in neuronal death induced by neurotoxic ␤-amyloid peptides (A␤). In particular, to test this hypothesis, three main questions were addressed: 1) whether the A␤ peptide can up-regulate both the transcription/translation and activity of K V 3.4 channel subunit and its accessory subunit, MinK-related peptide 2 (MIRP2); 2) whether the increase in K V 3.4 expression and activity can be mediated by the nuclear factor-B (NF-B) family of transcriptional factors; and 3) whether the specific inhibition of K V 3.4 channel subunit reverts the A␤ peptide-induced neurodegeneration in hippocampal neurons and nerve growth factor (NGF)-differentiated PC-12 cells. We found that A␤ 1-42 treatment induced an increase in K V 3.4 and MIRP2 transcripts and proteins, detected by reverse transcription-polymerase chain reaction and Western blot analysis, respectively, in NGF-differentiated PC-12 cells and hippocampal neurons. Patch-clamp experiments performed in whole-cell configuration revealed that the A␤ peptide caused an increase in I A current amplitude carried by K V 3.4 channel subunits, as revealed by their specific blockade with blood depressing substance-I (BDS-I) in both hippocampal neurons and NGF-differentiated PC-12 cells. The inhibition of NF-B nuclear translocation with the cell membrane-permeable peptide SN-50 prevented the increase in K V 3.4 protein and transcript expression. In addition, the SN-50 peptide was able to block A␤ 1-42 -induced increase in K V 3.4 K ϩ currents and to prevent cell death caused by A␤ 1-42 exposure. Finally, BDS-I produced a similar neuroprotective effect by inhibiting the increase in K V 3.4 expression. As a whole, our data indicate that K V 3.4 channels could be a novel target for Alzheimer's disease pharmacological therapy.
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Alteration of neuronal K
ϩ channel function, which is involved in the regulation of membrane excitability-including setting the resting potential, keeping action potentials short, and timing interspike intervals (Birnbaum et al., 2004 )-leads to remarkable perturbations in neuronal function. In particular, intracellular potassium concentrations ([K ϩ ] i ) play a key role in cell survival. Indeed, a decrease in cytoplasmic [K ϩ ] i , mainly caused by an increased activity of plasma membrane voltage-gated potassium (K V ) channels, triggers cell death (Yu et al., 1997 (Yu et al., , 1999a Lauritzen et al., 2003) , possibly by activating nucleases (Bortner et al., 1997) and caspases (Hughes and Cidlowski, 1999 ) that, in turn, propagate and amplify death signals. The involvement of K ϩ currents in neuronal apoptosis (Yu, 2003) is also supported by the fact that the inhibition of K ϩ efflux, induced by a wide range of K ϩ channel blockers or by the increase in extracellular K ϩ concentration, fully prevents cell death (Pike et al., 1996; Colom et al., 1998) . Recent research has demonstrated that changes in K ϩ channel activity play a major pathogenetic role in many neurodegenerative disorders, including Alzheimer's disease (AD). In fact, ␤-amyloid fragments (A␤), generated upon processing of the integral membrane amyloid precursor protein (Suh and Checler, 2002) , alter the properties of K ϩ currents in mammalian neurons (Jalonen et al., 1997; Yu et al., 1998; Jhamandas et al., 2001; Ramsden et al., 2001; Pannaccione et al., 2005) . Furthermore, a study performed on SN56 cells, a cholinergic cell line from rat, reported that treatment with A␤ increased the amount of delayed rectifier K ϩ currents and increased cell death (Colom et al., 1998) . Among the different K V currents exhibiting distinct biophysical properties, fast-inactivating K ϩ currents (I A ), which are known to contribute to action potential repolarization (Rudy and McBain, 2001) and to regulate interspike interval, have been suggested to participate in neurodegenerative processes (Birnbaum et al., 2004) . The genes encoding for several K V channel subunits that give rise to I A currents have been cloned. Among these are K V 4.1, 4.2, and 4.3 of the Shal family, K V 3.3 and 3.4 of the Shaw family, and K V 1.4 of the Shaker subfamily. These channel subunits differ in their pharmacology and biophysical characteristics. In particular, the expression and modulation of the K V 3 subfamily play a relevant role in axons and presynaptic terminal electrophysiological control. In fact, these channels are able to keep action potentials short and to facilitate recovery of processes that accumulate during repetitive action potentials. Furthermore, they can also limit the frequency of action potential transmission. One of the components of K V 3 family, namely K V 3.4, besides being present in skeletal muscle and in sympathetic ganglia (Rudy et al., 1999) , is also prominently expressed in the neurons of the adult dentate gyrus and in the mossy fibers of the hippocampus. In these neurons, K V 3.4 subunits seem to be predominantly expressed on axons and nerve terminals (Heinemann et al., 1996; Rudy et al., 1999) . Moreover, K V 3.4 subunits can form stable complexes with MinK-related peptide 2 (MIRP2). Such an interaction modifies the voltage-dependence of activation, speeds the recovery from inactivation, reduces the cumulative inactivation, and finally, affects unitary conductance of K V 3.4 channels (Abbott et al., 2001 (Abbott et al., , 2006 . In addition, K V 3.4 channel subunits can form heteromeric channels by coassembling with other members of the K V 3 subfamily, such as K V 3.1, K V 3.2, and K V 3.3 channel subunits (Rudy et al., 1999; Rudy and McBain, 2001) .
Although it has been demonstrated recently that A␤ 1-42 can potentiate the I A (Pannaccione et al., 2005) , the molecular identity of K ϩ channel subunit(s) modulated by the neurotoxic peptide has not yet been determined. Thus, we investigated whether K V 3.4 channel subunits and its accessory subunit MIRP2 are involved in A␤-induced I A modulation. In addition, the hypothesis that the overexpression and hyperactivity of K V 3.4 channels could be related to the apoptotic process induced by A␤ was evaluated by the inhibition of K V 3.4 channel and by the blockade of the nuclear translocation of NF-B, the transcription factor involved in A␤ neurotoxicity.
The data obtained showed that the A␤ peptide induced an increase in I A currents through an up-regulation of K V 3.4 channel subunit and MIRP2. Thus, the increase in K V 3.4 functional activity is involved in A␤ neurotoxicity.
Materials and Methods

Materials
␤-Amyloid peptide 1-42 (A␤ ) and all other unmentioned materials were from Sigma Chemical (St. Louis, MO). Primary antibodies against K V 3.4 and K V 3.3 channel subunits and MIRP2 ␤-subunits, as well as nerve growth factor (NGF 2.5S), tetrodotoxin, and blood depressing substance-I (BDS-I) were from Alomone Labs (Jerusalem, Israel). Primary antibody against caspase-3 and antirabbit IgG secondary antibody were purchased from Invitrogen (Carlsbad, CA). SN-50 and Protease Inhibitor Cocktail II were purchased from Calbiochem (San Diego, CA). RPMI 1640 medium, horse serum, fetal bovine serum, and phosphate-buffered saline (PBS) were from Invitrogen. L-Glutamine, fetal calf serum, Earle's balanced salt solution, TRIzol lysis buffer, and SuperScript III were from Invitrogen (Carlsbad, CA). Primers for K V were from Primm (Milan, Italy). AmpliTaq DNA Polymerase was from Eppendorf (Milan, Italy), and RNAase-free DNAase I was purchased from Stratagene (Milan, Italy). The marker Ladder, 100 bp, was purchased from New England Biolabs (Milan, Italy).
Cell Culture
PC-12 Cells. Rat pheochromocytoma cells (PC-12 cells) were grown as described previously (Pannaccione et al., 2005) . Cells were seeded at low density on glass coverslips coated with poly(L-lysine) (50 g/ml). Differentiation of PC-12 cells was achieved by treatment with NGF 2.5S (50 ng/ml) for 7 to 9 days (Greene and Tischler, 1976) .
Rat Hippocampal Neuronal Cultures. Hippocampal neurons were obtained from the brains of 18-day-old Wistar rat embryos (Charles River, Sulzfeld, Germany) as described previously (Scorziello et al., 2001) . Cytosine arabinoside at 5 M was added within 48 h of plating to prevent the growth of non-neuronal cells. In all experiments, neurons were cultured in a humidified atmosphere at 37°C with 5% carbonic anhydrase (CO 2 ) and used after 8 days of culturing.
Electrophysiology
K
ϩ currents were recorded from NGF-differentiated PC-12 cells and primary rat hippocampal neurons at 20°-22°C using a commercially available amplifier (Axopatch 200A; Molecular Devices, Sunnyvale, CA), as described previously (Pannaccione et al., 2005) . In most experiments, the patch-clamp technique in whole-cell configuration was performed using glass micropipettes of 2.5 to 4 M⍀ resistance. Currents were filtered at 5 kHz and digitized using a Digidata 1200 interface (Axon Instruments). Data were acquired and analyzed using the pClamp software (version 6.0.4; Axon Instruments). The pipette solution contained the following: 140 mM KCl, 2 mM MgCl 2 , 10 mM HEPES, 10 mM glucose, 10 mM EGTA, and 1 mM Mg-ATP adjusted at pH 7.4 with KOH. The extracellular solution contained the following: 150 mM NaCl, 5.4 mM KCl, 3 mM CaCl 2 , 1 mM MgCl 2 , and 10 mM HEPES, adjusted at pH 7.4 with NaOH. The extracellular solution for all experiments contained 50 nM tetrodotoxin.
To discriminate K ϩ current components having distinct inactivation properties (namely an inactivating component I A and a delayedrectifier noninactivating component I DR ), appropriate electrophysiological protocols were used. The total outward K ϩ current (I K ϭ I A ϩ I DR ) was measured by applying, from a holding potential of Ϫ80 mV, depolarizing voltage steps of 250-ms duration ranging from Ϫ80 to ϩ40 mV. These were preceded by conditioning pulses at Ϫ100 mV lasting for 1.5 s to allow full recovery from I A inactivation. Then, after conditioning pulses delivered at Ϫ40 mV lasting for 1.5 s fully inactivated I A , I DR was isolated by stepping from Ϫ80 to ϩ40 mV for 250 ms. The I A component was thus obtained by subtracting the isolated I DR component from the total K ϩ current. Current amplitudes were measured for I A and I DR at ϩ40 mV, either at the peak or at the end of the depolarizing pulse, respectively. Possible changes in 666 cell size occurring upon specific pharmacological treatments were calculated by monitoring the membrane capacitance of each cell, which is directly related to membrane surface area, and by expressing the current amplitude data as current densities (in picoamperes per picofarad). Capacitive currents were elicited by 5-mV depolarizing pulses from Ϫ80 mV and acquired at a sampling rate of 50 kHz. The capacitance of the membrane was calculated according to the following equation:
where C m is membrane capacitance, c is the time constant of the membrane capacitance, I o is the maximum capacitance current value, ⌬E m is the amplitude of the voltage step, and I ϱ is the amplitude of the steadystate current.
Assessment of Nuclear Morphology
Nuclear morphology was evaluated by using the fluorescent DNA binding dye bis-Benzimide H 33258 (Hoechst 33258; Aventis, Strasbourg, France). To this aim, cells were fixed in 4% paraformaldehyde and incubated for 5 min in PBS containing 1 g/ml Hoechst at 37°C. Coverslips were mounted on glass slides and observed with a fluorescence microscopy on a Nikon Eclipse E400 microscope (Nikon, Torrance, CA). Digital images were taken with a CoolSnap camera (Media Cybernetics Inc, Silver Spring, MD), stored on the hard-disk of a Pentium III computer, and analyzed with the Image-Pro Plus 4.5 software (Media Cybernetics Inc). Pathological nuclei were characterized by chromatin condensation (pyknosis), fragmentation, or by a decrease in size.
mRNA Analysis by Reverse-Transcription Polymerase Chain Reaction
Possible changes in RNA expression induced by A␤ 1-42 treatment were evaluated by semiquantitative RT-PCR. In brief, total RNA was extracted from NGF-differentiated (control) or A␤ 1-42 treated PC-12 cells using TRIzol lysis buffer (Invitrogen). To avoid contamination by genomic DNA, the extracted RNA was treated with 10 U/l RNase-free DNAase I for 1 h at 37°C. The purity and integrity of the RNA was checked by denaturing agarose gel electrophoresis. Total RNA (2 g) was reverse-transcribed by SuperScript III reverse transcriptase (Invitrogen) for 1 h at 50°C using oligo(dt) primers. The retrotranscribed cDNAs were amplified in an MJ Research Minicycler (MJ Reseach PTC 2000 Thermal Cycler; CELBIO, Milano, Italy) by the polymerase chain reaction using primers directed against several cDNAs (Table 1) . Primers directed against glyceraldehyde 3-phosphate dehydrogenase (GAPDH) cDNA were used as internal control. The amplification protocol (30 cycles) was the following: 94°C for 30 s, 50°C for 30 s, and 72°C for 1 min. Each 50-l reaction contained 1.25 U of AmpliTaq DNA Polymerase (Eppendorf) and 10 pmol of each primer. The amplification products were visualized on agarose (2%) gel electrophoresis by loading approximately half (25 l) of each reaction per lane. The acquisition and densitometric analysis of the RT-PCR products were realized using a ChemiDoc station (Bio-Rad, Milan, Italy).
Western Blot Analysis
Cells were washed in PBS and collected by gentle scraping in ice-cold lysis buffer to detect K V 3.4, K V 3.3, and MIRP2 proteins (Secondo et al., 2003) or immunoprecipitation assay buffer to detect caspase-3 protein expressions (Amoroso et al., 2002) . Both lysis buffers contained Protease Inhibitor Cocktail II (Roche Diagnostics, Monza, Italy). To evaluate K V 3.4, K V 3.3, and MIRP2 expressions, proteins (100 g per lane) were separated by SDS-polyacrylamide gel electrophoresis on 8% polyacrylamide gels and transferred onto nitrocellulose membranes (Hybond-ECL; GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK). K V 3.4, K V 3.3, and MIRP2 expressions were analyzed with anti-K V 3.4-, K V 3.3-, and MIRP2-polyclonal antibodies. For caspase-3 expression, proteins (50 g per lane) were separated by SDS-polyacrylamide gel electrophoresis on 12% polyacrylamide gels and transferred onto nitrocellulose membranes (Hybond-ECL; Amersham). Caspase-3 expression was analyzed with anti caspase-3-polyclonal antibody. The chemiluminescence detection was performed by using ECL Western Detection Kit (Amersham). Nonspecific binding sites were blocked by incubation for 2 h at room temperature with 5% nonfat dry milk (Bio-Rad) in Trisbuffered saline/Tween 20 buffer. Films were developed using a standard photographic procedure, and quantitative analysis of detected bands was carried out by densitometer scanning.
K V 3.4 Immunofluorescence
NGF-differentiated PC12 cells and hippocampal neurons, both during control condition and after 24 h of A␤ 1-42 exposure, were washed in cold PBS and fixed in 4% (w/v) paraformaldehyde in PBS for 30 min. After four washes in PBS, the cells were first preincubated in PBS containing 3% (w/v) bovine serum albumin (Sigma) and 0.05% (v/v) Triton X-100 (Bio-Rad) for 30 min and then with the primary anti N-terminal K V 3.4 polyclonal antibody (1:2000) at 4°C overnight. Next, cells were washed in PBS and finally incubated with the secondary antibody Alexa-fluor 546 anti-rabbit IgG (Molecular Probes; dilution, 1:200) for 1 h at room temperature. Cell nuclei were stained with Hoechst (Sigma). After the final wash, cells were mounted and placed on coverslips with Vectashield (Vector Laboratories, Burlingame, CA). Slides were analyzed with a Nikon Ecilpse 400 upright microscope (Nikon Instruments, Florence, Italy) equipped with a charge-coupled device digital camera (Coolsnap-Pro) and Image Pro-Plus software (both from Media Cybernetics).
␤-Amyloid Peptide Treatment
A␤ 1-42 was prepared as 0.1 mg/0.1 ml stock solution in sterile PBS, incubated at 37°C for 24 h to enhance aggregation, and stored at Ϫ20°C. Stock solution was directly diluted in cell culture media to give the desired experimental concentrations (5 M). Table 1 ), showed that A␤ 1-42 treatment (5 M for 24 h) induced a selective increase in K V 3.4 and MIRP2 mRNA expression but a decrease in K V 4.2 (Fig. 1) . By contrast, A␤-treatment did not modify K V 1.4, K V 3.1, K V 3.2, K V 3.3, K V 4.3, and MIRP1 mRNA (Fig. 1) .
Results
Up
Overexpression of K V 3.4 Channel and of Its Subunit MIRP2 Induced by A␤ 1-42 in NGF-Differentiated PC-12 Cells and in Hippocampal Neurons. Immunoblot analysis performed with a K V 3.4-specific antibody on protein extracts from NGF-differentiated PC-12 cells and hippocampal neurons revealed two bands, one at 75 kDa and the other at 110 kDa, that seem to correspond to native subunit monomer and to glycosylated subunit monomers (McMahon et al., 2004) , respectively (Fig. 2) . Densitometric analysis showed that the bands at 75 and 110 kDa were both significantly more intense in hippocampal neurons and NGF-differentiated PC-12 cells treated with A␤ 1-42 fragment than in the controls (Fig.  2, C and D) . In contrast, A␤ 1-42 treatment failed to modify K V 3.3 protein expression in these neurons (Fig. 2, A and B) . In addition, A␤ 1-42 exposure induced an increase in MIRP2 protein expression (Fig. 2) .
The K V 3.4 Inhibitor BDS-I Prevents A␤ 1-42 Induced Increase of I A Currents. Patch-clamp experiments, performed in hippocampal neurons, revealed that A␤ 1-42 treatment (5 M for 24 h) caused an increase in I A current amplitude, previously isolated with the voltage subtraction protocol described under Materials and Methods (Fig. 3) . I A currents, obtained upon subtraction of I DR from I K currents, were blocked by the extracellular application of the K V 3 subfamily inhibitor BDS-I (50 nM) (Diochot et al., 1998; Yeung et al., 2005) (Fig. 3) . The percentage of the BDS-I inhibition was higher in A␤ 1-42 -treated hippocampal neurons than in control neurons (Fig. 3D) . (Figs. 4, D, F , and G, and 5, B and C). It is interesting that the anti-K V 3.4 antibody revealed a pronounced perikaryal staining that was intensely confined to the somatic plasma membrane (Figs. 4, D, F , and G, and 5, B and C). In addition, double-labeling experiments of K V 3.4 channel subunits with the fluorescent-DNA binding dye Hoechst 33258 revealed that cells showing K V 3.4 channels immunoreactivity after amyloid peptide exposure also displayed an abnormal nuclear morphology (Figs. 4, B and E, and 5, A-a and C-c), thus suggesting that neurons over- expressing this K ϩ channel undergo apoptosis. This result was confirmed by Western blot analysis performed with a caspase-3-specific antibody on protein extracts from NGFdifferentiated PC-12 cells. In fact, A␤ 1-42 exposure induced an increase of caspase-3 expression (Fig. 4H) . Likewise, 24-h A␤ 1-42 exposure induced the activation of caspase-3 in hippocampal neurons (Fig. 5D) .
Prevention of A␤ 1-42 -Induced Apoptosis by BDS-I in NGF-Differentiated PC-12 Cells and in Hippocampal Neurons. BDS-I (50 nM), the K V 3 subfamily inhibitor, was able to significantly prevent the abnormal nuclear morphology induced by the exposure of NGF-differentiated PC-12 cells (Fig. 6, A and B) and of hippocampal neurons (Fig. 6, C and D) to A␤ 1-42 (5 M for 24 h), as detected by the Hoechst 32258 dye staining. (Fig. 7,  A and B) and Western blot analysis (Fig. 7, C and D) performed in the presence and in the absence of SN-50 (5 M)-a cell membrane-permeable peptide capable of inhibiting the nuclear translocation of NF-B complexes (Lin et al., 1995) -showed that this agent largely prevented the increase in K V 3.4 mRNA and protein expression, respectively, caused by A␤ 1-42 exposure (5 M, 24 h). Furthermore SN-50, the NF-B inhibitor, was able to prevent A␤ 1-42 -induced increase of I A current (Fig. 7E) .
Prevention of Protein and Transcript Expression of K V 3.4 Channel Subunits and of Apoptotic Nuclear Features by the Inhibition of NF-B Nuclear Translocation in NGF-Differentiated PC-12 Cells. RT-PCR
Discussion
In this study, we provide evidence that hippocampal neurons and NGF-differentiated PC-12 cells exposed to A␤ 1-42 treatment display a selective up-regulation of K V 3.4 channel subunits through the activation of the transcriptional factor NF-B. In addition, this transcriptional event is associated with a current increase carried by this channel. It is interesting that the action of A␤ was not limited to the poreforming K V 3.4 subunit. Indeed, it also induced an overexpression of MIRP2, a neuronal ␤-subunit coassembling with K V 3.4 subunit and playing a crucial role in the control of its biophysical properties and pharmacological profile (Abbott et al., 2001 (Abbott et al., , 2006 . Such MIRP2 overexpression might profoundly interfere with the function of pore-forming K V 3.4 ␣-subunits, suggesting that the neurotoxic A␤ peptide might influence the I A current by modulating simultaneously the pore-forming ␣-subunit and its accessory component expression.
On the other hand, A␤ 1-42 exposure selectively modulated the expression and the activity of K V 3.4 channel subunits because the amyloid peptide did not modify the mRNA expression of the other K V channels, K V 1.4, K V 3.1, K V 3.2, K V 3.3, and K V 4.3 subunits. In agreement with biochemical and electrophysiological results, the immunocytochemical analysis confirmed that the A␤ 1-42 -induced up-regulation of K V 3.4 channel subunit was associated with an altered subcellular distribution of this protein. In fact, A␤ 1-42 treatment induced a more intense staining for K V 3.4 subunits; after A␤ 1-42 treatment, K V 3.4 immunoreactivity was mainly confined to the somatic plasma membrane, compared with that of control cells in which the fluorescent signal was mostly distributed through the neuropil. This different K V 3.4 distribution induced by the neurotoxic peptide could be caused by the altered integrity of the cytoskeletal network prompted by oligomeric or fibrillar forms of A␤ (Michaelis et al., 2005) . These findings are in accordance with other experiments carried out with rhodaminate-phalloidin, a selective actin fluorescence staining, which revealed that A␤ 1-42 causes a cytoskeletal rearrangement (Pannaccione et al., 2005) . In addition, hippocampal neurons and NGF-differentiated PC-12 cells expressing increased K V 3.4 immunoreactivity showed an apoptotic nuclear process, as revealed by caspase-3 activation (Amoroso et al., 2002; Tamagno et al., 2006) and by Hoechst 33258-monitored abnormal nuclear morphology, thus suggesting a possible link between the enhanced expression and function of this K ϩ channel and the neurotoxic consequences prompted by A␤ exposure. That the exposure to A␤ fragments may alter the properties of K ϩ currents in mammalian neurons (Jalonen et al., 1997; Colom et al., 1998; Yu et al., 1998; Jhamandas et al., 2001; Ramsden et al., 2001; Pannaccione et al., 2005) and therefore may cause an increase in cell death as a result of a decrease in cytoplasmic K ϩ concentrations (Bortner et al., 1997; Hughes and Cidlowski, 1999) has already been reported. Nevertheless, the molecular identification of the K ϩ channel involved has been a matter of debate. In particular, Pan et al. (2004) showed that a single intracerebroventricular injection of A␤ [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] in rat up-regulates K V 1.4 and K V 2.1 expression in the hippocampus and K V 4.2 in the cortex. Likewise, an upregulation of K V 4.2 channel subunit, carrying I A current, has also been observed in rat cerebellar granule cells exposed to neurotoxic A␤ peptides (Plant et al., 2006) . By contrast, in the present study, the expression of K V 4.2 mRNA was downregulated by neurotoxic A␤ 1-42 . It is noteworthy that the expression of K V 4.2 gene can be differentially regulated in different cell types or by following several injury models (Tsaur et al., 1992; Jia and Takimoto, 2003) .
The hypothesis that K V 3.4 channels are involved in the A␤ 1-42 neurotoxic effect was further supported by the results showing that BDS-I, a K V 3.4 blocker (Diochot et al., 1998) , exerted a potent neuroprotective action in hippocampal neurons and NGF-differentiated PC-12 cells exposed to A␤ peptide. On the other hand, the possibility that the neuroprotective action of BDS-I is also caused by a blockade of the other HK V 3 subfamily members K V 3.1, K V 3.2, and K V 3.3 (Yeung et al., 2005) does not seem a likely explanation because their expression is unmodified after A␤ peptide exposure.
Regarding the NF-B family of transcriptional factors, their involvement in AD pathogenesis has long been corroborated by insightful evidence. In fact, an increased NF-B activity has been detected in neurons and astrocytes in the immediate vicinity of amyloid plaques in brain sections from patients with AD (Ferrer et al., 1998) ; furthermore, a significant NF-B activation in primary neuronal cells exposed to A␤ peptides has also been documented (Barger and Mattson, 1996) . In addition, data obtained previously in our laboratory (Pannaccione et al., 2005) have revealed that the highly specific and cell membrane-permeable NF-B inhibitor SN-50 (Lin et al., 1995) exerts a significant neuroprotective effect upon A␤ 1-42 exposure (Pannaccione et al., 2005) . In the present study, SN-50 largely prevented the increase in K V 3.4 protein expression and activity triggered by A␤ 1-42 exposure, suggesting that NF-B mediates the transcriptional regulation of K V 3.4 occurring during A␤ exposure. Further evidence that the increased expression of K V 3.4 channels was caused by the stimulation of protein transcription and synthesis rather than by an inhibition of its catabolism is that K V 3.4 mRNA also increased. In addition, other experiments have revealed that the protein synthesis inhibitor cycloheximide and the transcriptional inhibitor actinomycin D fully prevent A␤-induced K ϩ currents (Pannaccione et al., 2005) . It is interesting that cDNA array analysis has also demonstrated that the K V 3.4 gene is up-regulated in the brain extracts of transgenic mice with the amyloid precursor protein 695 Swedish mutation and in the cerebral cortex of patients in the early and later stages of AD (Angulo et al., 2004) .
As a whole, our data suggest that A␤ 1-42 fragment exposure causes the up-regulation not only of K V 3.4 but also of its accessory subunit MIRP2. This increased expression is associated with an enhanced activity of the K ϩ current carried by this channel. Furthermore, the changes resulting from this channel activation may contribute to a reduction in [K ϩ ] i , which in turn triggers the apoptotic process, as already demonstrated (Yu, 2003) .
In conclusion, the relationship between K V 3.4 and apoptotic cell death is demonstrated in the current study by the fact that the blockade of this channel was able to prevent the apoptotic process triggered by A␤ 1-42 fragment. These results reveal new and additional therapeutic strategies for AD using selective voltage-dependent potassium channels as molecular targets.
